The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV)
Cytomegalovirus (CMV) is a leading cause of congenital infections and significant health complications in immunocompromised individuals. With no licensed CMV vaccine available, the development of the mRNA-1647 offers promising advancements in CMV prevention. We have reviewed results from Phase 1 and...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2450045 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832595663073837056 |
|---|---|
| author | Adewunmi Akingbola Abiodun Adegbesan Olajumoke Adewole Kolade Adegoke Akpevwe Emmanuella Benson Paul Ayomide Jombo Sandra Uchechukwu Eboson Victor Oluwasola Ademola Aiyenuro |
| author_facet | Adewunmi Akingbola Abiodun Adegbesan Olajumoke Adewole Kolade Adegoke Akpevwe Emmanuella Benson Paul Ayomide Jombo Sandra Uchechukwu Eboson Victor Oluwasola Ademola Aiyenuro |
| author_sort | Adewunmi Akingbola |
| collection | DOAJ |
| description | Cytomegalovirus (CMV) is a leading cause of congenital infections and significant health complications in immunocompromised individuals. With no licensed CMV vaccine available, the development of the mRNA-1647 offers promising advancements in CMV prevention. We have reviewed results from Phase 1 and 2 clinical trials of the mRNA-1647 vaccine, demonstrating robust immune responses in both seronegative and seropositive participants. Vaccines exhibited significantly elevated neutralizing antibody titers against CMV, particularly in fibroblast and epithelial cells, with sustained responses lasting up to 18 months post-vaccination. The mRNA-1647 vaccine triggered strong T-cell and memory B-cell responses, suggesting its potential for long-term protection against CMV infection. The ongoing Phase 3 CMVictory trial evaluates the safety and immunogenicity of mRNA-1647 in women of childbearing age, with preliminary data showing promise in preventing congenital CMV transmission. This vaccine could significantly reduce CMV-related morbidity and mortality, particularly in newborns and immunocompromised individuals, addressing a critical unmet medical need. |
| format | Article |
| id | doaj-art-1c7e417c5a754cf782dd0fdf8b004103 |
| institution | Kabale University |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-1c7e417c5a754cf782dd0fdf8b0041032025-01-18T05:48:35ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2450045The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV)Adewunmi Akingbola0Abiodun Adegbesan1Olajumoke Adewole2Kolade Adegoke3Akpevwe Emmanuella Benson4Paul Ayomide Jombo5Sandra Uchechukwu Eboson6Victor Oluwasola7Ademola Aiyenuro8Department of Public Health, University of Cambridge, England, UKAfrican Cancer Institute, Department of Global Health, Stellenbosch University, Cape Town, South AfricaDepartment of Medicine, Iwosan-Lagoon Hospitals, Lagos, NigeriaFaculty of Clinical Sciences, Obafemi Awolowo University Ile-Ife, Osun State,NigeriaFaculty of Pharmacy, University of Benin, Benin City, Edo State, NigeriaInternal Medicine, Basildon and Thurrock University Hospitals NHS Foundation Trust: Basildon SS165NL, England, Essex, England, UKDeggendorf Institute of Technology, European Campus Rottal-Inn, Deggendorf, GermanyBabcock University Teaching Hospital, Ilishan-Remo, Ogun State, NigeriaDivision of Virology, Department of Pathology, University of Cambridge, England, UKCytomegalovirus (CMV) is a leading cause of congenital infections and significant health complications in immunocompromised individuals. With no licensed CMV vaccine available, the development of the mRNA-1647 offers promising advancements in CMV prevention. We have reviewed results from Phase 1 and 2 clinical trials of the mRNA-1647 vaccine, demonstrating robust immune responses in both seronegative and seropositive participants. Vaccines exhibited significantly elevated neutralizing antibody titers against CMV, particularly in fibroblast and epithelial cells, with sustained responses lasting up to 18 months post-vaccination. The mRNA-1647 vaccine triggered strong T-cell and memory B-cell responses, suggesting its potential for long-term protection against CMV infection. The ongoing Phase 3 CMVictory trial evaluates the safety and immunogenicity of mRNA-1647 in women of childbearing age, with preliminary data showing promise in preventing congenital CMV transmission. This vaccine could significantly reduce CMV-related morbidity and mortality, particularly in newborns and immunocompromised individuals, addressing a critical unmet medical need.https://www.tandfonline.com/doi/10.1080/21645515.2025.2450045CytomegalovirusmRNA-1647vaccinecongenital infectionimmunogenicitypublic health |
| spellingShingle | Adewunmi Akingbola Abiodun Adegbesan Olajumoke Adewole Kolade Adegoke Akpevwe Emmanuella Benson Paul Ayomide Jombo Sandra Uchechukwu Eboson Victor Oluwasola Ademola Aiyenuro The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV) Human Vaccines & Immunotherapeutics Cytomegalovirus mRNA-1647 vaccine congenital infection immunogenicity public health |
| title | The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV) |
| title_full | The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV) |
| title_fullStr | The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV) |
| title_full_unstemmed | The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV) |
| title_short | The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV) |
| title_sort | mrna 1647 vaccine a promising step toward the prevention of cytomegalovirus infection cmv |
| topic | Cytomegalovirus mRNA-1647 vaccine congenital infection immunogenicity public health |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2025.2450045 |
| work_keys_str_mv | AT adewunmiakingbola themrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT abiodunadegbesan themrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT olajumokeadewole themrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT koladeadegoke themrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT akpevweemmanuellabenson themrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT paulayomidejombo themrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT sandrauchechukwueboson themrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT victoroluwasola themrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT ademolaaiyenuro themrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT adewunmiakingbola mrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT abiodunadegbesan mrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT olajumokeadewole mrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT koladeadegoke mrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT akpevweemmanuellabenson mrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT paulayomidejombo mrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT sandrauchechukwueboson mrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT victoroluwasola mrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv AT ademolaaiyenuro mrna1647vaccineapromisingsteptowardthepreventionofcytomegalovirusinfectioncmv |